Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle.

Deciphering which businesses can sustain their high growth rates is a challenge for even the most seasoned professionals, which is why we started StockStory. Keeping that in mind, here are three growth stocks with significant upside potential.

AppLovin (APP)

One-Year Revenue Growth: +21.1%

Sitting at the crossroads of the mobile advertising ecosystem with over 200 free-to-play games in its portfolio, AppLovin (NASDAQ: APP) provides software solutions that help mobile app developers market, monetize, and grow their apps through AI-powered advertising and analytics tools.

Why Are We Backing APP?

1. Market share has increased as its 30.9% annual revenue growth over the last two years was exceptional
2. User-friendly software enables clients to ramp up spending quickly, leading to the speedy recovery of customer acquisition costs
3. Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends

AppLovin’s stock price of $659 implies a valuation ratio of 32.1x forward price-to-sales. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.

Doximity (DOCS)

One-Year Revenue Growth: +20.2%

With over 80% of U.S. physicians as members of its digital community, Doximity (NYSE: DOCS) operates a digital platform that enables physicians and other healthcare professionals to collaborate, stay current with medical news, manage their careers, and conduct virtual patient visits.

Why Is DOCS a Top Pick?

1. Winning new contracts that can potentially increase in value as its billings growth has averaged 20.1% over the last year
2. Fast payback periods on sales and marketing expenses allow the company to invest heavily and onboard many customers concurrently
3. Strong free cash flow margin of 50.2% enables it to reinvest or return capital consistently

At $44.04 per share, Doximity trades at 13x forward price-to-sales. Is now a good time to buy? See for yourself in our full research report, it’s free for active Edge members.

Bowhead Specialty (BOW)

One-Year Revenue Growth: +33.4%

Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE: BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.

Why Will BOW Beat the Market?

1. Strong 37.9% annualized net premiums earned expansion over the last two years shows it’s capturing market share this cycle
2. Expected revenue growth of 20.7% for the next year suggests its market share will rise
3. Balance sheet strength has increased this cycle as its 74.5% annual book value per share growth over the last two years was exceptional

Bowhead Specialty is trading at $28.09 per share, or 2.1x forward P/B. Is now the right time to buy? Find out in our full research report, it’s free for active Edge members.

High-Quality Stocks for All Market Conditions

Your portfolio can’t afford to be based on yesterday’s story. The risk in a handful of heavily crowded stocks is rising daily.

The names generating the next wave of massive growth are right here in our Top 5 Strong Momentum Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today for free. Find your next big winner with StockStory today. Find your next big winner with StockStory today.